The Paper Millionaire: What Your Rollover Equity Is Actually Worth

At the closing dinner, everyone toasts the headline number. Five million dollars.

Here is what actually happened at the wire: $2,750,000 arrived in the seller’s account. $750,000 went into escrow for two to three years. And $1,500,000 — roughly thirty percent of a life’s work — became stock in a company that had been courting them to get the deal to the finish line.

That last piece is rollover equity, and it has a better marketing department than any instrument in dental M&A.

The anatomy of the headline

Component	Share	Dollars	What it actually is
Cash at close	55%	$2,750,000	A fact
Escrow holdback, 24–36 months	15%	$750,000	A probability — the buyer can charge pre-existing conditions against it
Rollover equity	30%	$1,500,000	A thesis — stock in the buyer’s platform, where you have limited control (if any)
Headline	100%	$5,000,000	The number told to peers

Source: Precision Dental Analytics illustrative structure; component ranges per prevailing DSO deal terms (cash at close typically 40–60%, escrow 15–20%, rollover 20–40%).

Rollover equity is the portion of your price you reinvest into the buyer’s platform instead of taking as cash. The pitch is the “second bite of the apple”: the platform grows, recapitalizes on roughly a five-year cycle, and your stake is monetized at the platform’s multiple — the whole allure, because platforms trade at 9–14× EBITDA while they bought your practice at 5–8×. The arbitrage is real; it is the engine of the entire consolidation model. When the second bite pays, it can genuinely exceed the first.

But read what you just accepted. You sold the asset you controlled completely — whose numbers you could audit any morning before 7am — and took payment in the one asset class you cannot audit at all.

The asymmetry nobody mentions at the dinner

Before that buyer wired a dollar, they spent 90 days inside your practice. A Quality of Earnings team extracted five years of your PMS data, benchmarked your coding patterns, stress-tested your add-backs, re-priced your working capital, and modeled your provider dependency. They diligenced you to the last decimal — the same asymmetric diligence that strips value from unprepared sellers.

Now ask: what diligence did you run on them?

You are not just selling to this platform. You are investing 20 to 40 percent of your net worth into it. And in deal after deal, the seller’s diligence on the buyer amounts to a growth story over dinner and a logo slide.

They audit you for 90 days. You audit them for much less — and without the same sophistication. Same transaction, same table — only one side brings forensics.

What the paper is exposed to

Your rollover stake is a minority position, in an illiquid private company, that is usually leveraged, whose books you will never audit, whose valuation marks you cannot verify, and whose exit timing you do not control. Every clause in that sentence is a risk you would never accept inside your own practice.

The platform’s debt comes ahead of your equity. The recap that monetizes your second bite happens on the sponsor’s schedule, not yours — and when financing markets tighten, recapitalizations get postponed while your paper waits. The private-equity playbook in healthcare runs on leverage, and leverage is patient with everyone except minority holders.

And here is the part every seller should sit with: after closing, your own compensation, lab fees, and production targets are set by the platform — because your practice’s margin is now a line item in the EBITDA number that determines what their next buyer pays. You are not just holding their stock. You are working for their exit.

None of this makes rollover equity a scam. Sometimes the second bite is the best money in the deal. It makes rollover equity a security — and securities get diligenced.

The audit you should run on them

Five questions before you accept a single share:

1. Leverage. What is the platform’s debt, and what does service look like against current EBITDA? A platform that must grow to survive is a different investment than one that chooses to.
2. Fund-cycle position. Rolling into year one of a fund and rolling into year six are different bets on when — and whether — your recap arrives.
3. Track record. Prior recapitalizations, multiples actually paid, and what earlier rollover holders realized. Track records exist. Ask.
4. Equity class and waterfall. What are you receiving, and who stands ahead of you? Your attorney maps it before you sign, not after.
5. How platform EBITDA is manufactured. If the answer includes compressing the compensation of the doctors who rolled equity — you will be funding your own second bite.

If a buyer resists these questions, that is also an answer.

The bottom line

Cash at close is a fact. Escrow is a probability. Rollover equity is a thesis — about someone else’s company, someone else’s leverage, and someone else’s exit.

Thirty percent of your life’s work deserves more diligence than a dinner. The full deal-structure reference covers how each component is negotiated; the exit timeline covers when this preparation has to start — and as with everything at the closing table, the tax treatment of what you keep is decided by structure, not by the headline.

---

Educational, not investment, legal, or tax advice — rollover structures, equity classes, and tax treatment vary by deal; run yours past your attorney and CPA. To see what the buyer’s 90-day audit will find in your practice before they do, start with the EBITDA Leakage Diagnostic or the free Defense Gap field guide.

About the author — James DeLuca is the founder of Precision Dental Analytics and a leading expert in Clinical Data Forensics and M&A Defense. Acting as the elite “Red Team” for multi-location founders and sell-side brokers, he mathematically hardens clinical architecture before founders face institutional due diligence. He is the author of Phantom EBITDA, Spartan Leadership, The Dental Data Playbook, and Hidden Levers. Meet the team →